ReviewCurrent heart failure reports2012
Prognostic value of combining echocardiography and natriuretic peptide levels in patients with heart failure.
Review in Current heart failure reports, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Peripheral Blood Mononuclear Cells and Platelets Mitochondrial Dysfunction, Oxidative Stress, and Circulating mtDNA in Cardiovascular Diseases.Journal of clinical medicine · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heart failure (HF) is still a global public health issue, despite the enormous progress made in its diagnosis and treatment. More often than not, acute or chronic decompensated HF leads to hospitalization and presents a dismal prognosis. Evidently, clinical symptoms alone are not reliable enough guidance for the HF treatment; therefore, parameters able to identify adverse prognoses are valuable in tailoring treatment regimens for individual patients. Echocardiography and natriuretic peptides (NPs) have demonstrated their capacities in giving independent diagnostic and prognostic information regarding patients with HF. Although abnormalities either of an echocardiographic index of left ventricular function or of an NP denote an increased risk of mortality or HF, the highest risk comes from abnormalities of both left ventricular function and NP levels. In this review, we survey the most recent publications exploring the utility of NP levels and echocardiographic indices integration, claimed to offer powerful incremental prognostication in patients with established HF.
Indexed as
Identifiers
22351121What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.